Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the third quarter 2011. Onyx reported a non-GAAP net loss of $19.5 million, or $0.31 per diluted share, for the third quarter 2011 compared to a non-GAAP net income of $55.3 million, or $0.84 per diluted share, for the same period in 2010. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

"We are continuing our strong momentum in 2011, building two robust oncology platforms – one in kinase inhibition and the other in proteasome inhibition," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The submission of our new drug application for carfilzomib demonstrates our commitment to getting this important therapy to patients as quickly as possible. For the kinase inhibitor business, Nexavar delivered another quarter of solid operating performance, primarily driven by sales growth in the Asia Pacific and U.S. regions, and we continue to see even more opportunity with this therapy in the approved indications and, potentially, other tumor types. The recent Bayer settlement also gives us a significant interest in regorafenib, and with a successful pivotal trial in colorectal cancer, we are excited about the prospect of this new therapy for patients."

Recent business highlights include submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during September 2011 under the accelerated approval process for carfilzomib, and the restructuring of our partnership with Bayer HealthCare Pharmaceuticals Inc., or Bayer, during October 2011 for the global development and marketing of Nexavar® (sorafenib) tablets. The Company also entered into a new agreement with Bayer related
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014 /PRNewswire/ ... Neuropathy Foundation (HNF), both philanthropies, announced today the ... candidates for the treatment of the rare disease ... BioPontis Alliance announced its alliance model earlier this ... first demonstration of a collaborative model where researchers ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... 20, 2014 JZ Fitness, an independently ... corporate wellness programming, authorship, international lecturing and community wellness, ... announce the release of the JZ Fitness nutrition app, ... of coaching thousands of individuals on nutrition, Jenn Zerling ... does not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, ... estimates member hospital ROI on membership dues at 12.5. In ... provides $12.50 in value to member hospitals. The calculation used ... Dues)/Member Dues. , “This is the first time we’ve ... think the methodology is really sound,” said Bill Ryan ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... celebrating his one Year Anniversary as a Non-Smoker 60 Pounds Lighter. What ... quit smoking or lose 60 pounds but to do both within one year ... was able to turn his life around and improve his quality of life; ... , ...
... voice preference on two California reorganization plans , ... members began casting ballots this week in an advisory vote ... register their preferences on whether they want to be part ... a new statewide local representing a broader classification of healthcare ...
... County Health Director, Dr. Bob England Encourage all Families to ... One Middle School , , ... that Arizona has its first lab-confirmed case of influenza in ... Public Health, the Arizona Department of Health Services, the Arizona ...
... announced today the Company will hold an,investor conference call to discuss current business conditions ... is,(866) 901-2585. The international call in number is (404) 835-7099. , , ... & ... ctrego@minrad.com , ...
... Consulting Inc.,announces the addition of two new areas of ... engineering and technology,services. The company is also launching its ... The company has realigned its services into ... sustainability. , "We ...
... useful, studies find , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... diabetes was no better at predicting a person,s risk for ... , The news is both encouraging and discouraging. , "The ... risk," said Dr. James Meigs, lead author of one of ...
Cached Medicine News:Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 2Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 3Health News:Advisory Vote Begins on California Long-Term Care Local 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 3Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 4Health News:Environmental and Technology Firm Integral Consulting Inc. Expands Services, Launches New Website 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 3
Cytomegalovirus IgG ELISA....
Cytomegalovirus IgM ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Microforceps: Diamond Dusted Micro Pic Forceps...
Medicine Products: